This phase II trial is trying to determine how effective a new biological therapy (RO7198457) and immunotherapy combination is, compared to immunotherapy on its own, in the treatment of advanced melanoma.
This trial is treating patients with melanoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase II, Open-Label, Multicenter, Randomized Study Of The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab In Patients With Previously Untreated Advanced Melanoma
Eligible participants will be randomised to receive 200 mg pembrolizumab administered intravenously (by IV) with or without a recommended dose of RO7198457. Participants in Arm A will be given the option of crossing over to combination treatment with RO7198457 plus pembrolizumab (Arm B) after (if) disease progression is confirmed.
Recruiting Hospitals Read More